Crystal tombstone celebrating a favorable verdict in an antitrust action against Gilead Sciences. The claim had centered on an earlier patent settlement involving Gilead and Teva. (23AKL380)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Crystal tombstone celebrating a favorable verdict in an antitrust action against Gilead Sciences. The claim had centered on an earlier patent settlement involving Gilead and Teva. (23AKL380)
Lucite deal tombstone commemorating two related royatly transactions. Both deals involve the diabetes drug TZIELD. (23AKL274)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
Diamond-shaped crystal deal toy commemorating a follow-on stock offering by Swiss biotech firm Oculis. (23AKL262)
Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Lucite deal tombstone recognizing the merger of Adatptimmune and TCR2 Therapeutics. Both companies develop treatments that re-engineer immune cells to treat cancer. (23AKL209)
Crystal deal tombstone marking a follow-on offering by life sciences company Intelligent Bio Solutions The design incorporates the firm’s drug screening cartridge. (23AJH030)
Crystal financial tombstone marking a private placement by Midatech Pharma. The drug delivery technology firm is based in the UK. (23AJH028)
Crystal financial tombstone celebrating Series A funding for Lokavant. Based in New York, Lokavant provides a centralized data repository for clinical drug trials. (23AKL083)
Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
